Delayed hypersensitivity reaction to cetirizine suggesting involvement of piperazine ring: a case report
Main Article Content
Keywords
cetirizine, Drug-induced maculopapular rashes, piperazine, delayed hypersensitivity, Antihistamines
Abstract
Antihistamines (AHs) are widely prescribed for allergic conditions and are generally considered safe, with adverse reactions being rare. We report a case highlighting the possible involvement of piperazine ring in a delayed hypersensitivity reaction. A 25-year-old woman with a history of atopic dermatitis progressively developed a maculopapular drug eruption following intake of cetirizine. Patch testing was negative, but oral provocation with cetirizine reproduced the rash, confirming its causal role. Importantly, oral provocation with ciprofloxacin, which also contains a piperazine ring, elicited a similar reaction, supporting that this structural moiety itself was responsible for hypersensitivity. Alternatively, AHs lacking the piperazine ring, such as in bilastine and rupatadine, were well tolerated. This case provides the first direct evidence of delayed hypersensitivity manifesting as a maculopapular drug eruption, probably because of the piperazine ring, with cross-reactivity observed between structurally unrelated drugs. Clinicians should be aware of the potential for structural moi-ety-driven hypersensitivity to prevent recurrence across different drug classes.
References
2. Barbaud A. Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep. 2014;14:442. https://doi.org/10.1007/s11882-014-0442-8
3. Caballero ML, Quirce S. Delayed hypersensitivity reactions caused by drug excipients: A literature review. J Investig Allergol Clin Immunol. 2020;30(6):400–8. https://doi.org/10.18176/jiaci.0562
4. Shakouri AA, Bahna SL. Hypersensitivity to antihistamines. Allergy Asthma Proc. 2013;34:488–96. https://doi.org/10.2500/aap.2013.34.3699
5. Naim M, Weyers W, Metze D. Histopathologic features of exanthematous drug eruptions of the macular and papular type. Am J Dermatopathol. 2011;33:695–704. https://doi.org/10.1097/DAD.0b013e31820a285d
6. Cusano F. Clinicopathologic features of systemic contact dermatitis from ethylenediamine in cetirizine and levocetirizine. Dermatology. 2006;213:353–5. https://doi.org/10.1159/000096203
7. Piapan L, Belloni Fortina A, Giulioni E, Larese Filon F. Sensitization to ethylenediamine dihydrochloride in patients with contact dermatitis in northeastern Italy from 1996 to 2021. Contact Dermatitis. 2024;90:253–61. https://doi.org/10.1111/cod.14454
8. Lew BL, Haw CR, Lee MH. Cutaneous drug eruption from cetirizine and hydroxyzine. J Am Acad Dermatol. 2004;50:953–6. https://doi.org/10.1016/j.jaad.2003.11.048
https://doi.org/10.1016/S0190-9622(03)04516-X
9. Stingeni L, Caraffini S, Agostinelli D, Ricci E, Lisi P. Maculopapular and urticarial eruption from cetirizine. Contact Dermatitis. 1997;37:249–50. https://doi.org/10.1111/j.1600-0536.1997.tb02456.x
10. Barbaud A, Garvey LH, Torres M, Laguna JJ, Arcolaci A, Bonadonna P, et al. EAACI/ENDA position paper on drug provocation testing. Allergy. 2024;79(3):565–79. https://doi.org/10.1111/all.15996
11. Zhu LJ, Liu AY, Wong PH, Arroyo AC. Road less traveled: Drug hypersensitivity to fluoroquinolones, vancomycin, tetracyclines, and macrolides. Clin Rev Allergy Immunol. 2022;62:505–18. https://doi.org/10.1007/s12016-021-08919-5
12. Alsubaiei F, Tétart F, Boulard C, Leblanc C, Joly P. Bullous fixed drug eruption to hydroxyzine and cross-reactivity with piperazine derivatives. Ann Dermatol Venereol. 2017;144:S139. https://doi.org/10.1016/j.annder.2017.09.187 (Article in French; English abstract available.)
13. Durand C, Szostak M. Recent advances in the synthesis of piperazines: Focus on C–H functionalization. Organics. 2021;2:337–47.1. https://doi.org/10.3390/org2040018